1Luscher TF,Enseleit F,Pacher R,et al.Hemodynamic and neurohumoral effects of selective endothelin A(ETA) receptor blockade in chronic heart failure.The heart failure ETA receptor blockade Trial(HEAT)[J].Circulation,2002,106(19):2666-2672.
2Spieker LE,Noll G,Ruschitzka FT,et al.Endothelin receptor antagonists in congestive heart failure:a new therapeutic principle for the future[J].J Am Coll Cardiol,2001,37(6):1493-1505.
3Cowburn PJ,Cleland JGF.Endothelin antagonists for chronic heart failure:do they have a role[J]? Eur heart J,2001,22(19):1772-1784.
4Denver R,Tzanidis A,Martin P,et al.Salivary endothelin concentrations in the assessment of chronic heart failure[J].Lancet,2000,355(5):468-469.
5Onishi K,Ohno M,Little WC,et al.Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure[J].J Pharmacol Exp Ther,1999,288(3):1214-1222.
6Kiowski W,Sutsch G,Hunziker P,et al.Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure[J].Lancet,1995,346(8977):732-736.
7Mulder P,Richard V,Derumeaux,et al.Role of endogenous endothelin in chronic heart failure[J].Circulation,1997,96(6):1976-1982.
8Wang XW,Ohnishi M,Wada A,et al.Endothelin-1 promotes vascular remodeling using a specific endothelin-coverting enzyme inhibitor[J].Life Sci,2001,69(21):2477-2488.
9Love MP,Ferro CJ,Haynes WG,et al.Endothelin receptor antagonism in patients with chronic heart failure[J].Cardiovasc Res,2000,47(1):166-172.
10Sutsch G,Kiowski W,Yan XW,et al.Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure[J].Circulation,1998,98(21):2262-2268.
2Ho KK, Anderson KM, Kannel WB, et al. Survivalafter the onset of congestive heart failure in Framingham Heart Study subjects[J]. Circulation, 1993, 88(1):107- 115.
3Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J]. Nature, 1988, 332(6163) :411 - 415.
4Sutsch G, Kiowski W. Endothelin and endothelin receptor antagonist in heart failure [J]. J Cardiovasc Pharmacol,2000, 35(4 Suppl 2):S69- S73.
5Turer A J, Tanzawak K. Mammalian member metallopeptidases: NEP, ECE, KELL and PEX[J]. FASEB J, 1997,11:355 - 364.
6Webb DJ, Monge JC, Rabelink TJ, et al. Endothelin: new discoveries and rapid progress in the clinic [J]. Trends PharmacolSci, 1998, 19(1):5-8.
7Masaki T. The endothelin family: an overview[J]. J Cardiovasc Pharmacol, 2000, 35(4 Suppl 2): S3 - S5.
8Elshourbagy NA, Korman DR, Wu HL, et al. Molecular characterization and regulation of the human endothelin receptors[J]. J Biol Chem, 1993, 268(6) :3873 - 3879.
9Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETc receptor) from Xenopus laevis dermal melanophores [J]. J Biol Chem, 1993, 268(25): 19126- 19133.
10Ogawa Y, Nakao K, Arai H, et al. Molecular cloning of a non-isopeptide-selective human endothelin receptor [J].Biochem Biophys Res Commun, 1991, 178(1) :248 - 255.
8Wei C M,lennan A,Rodeheffer R J,et al.Endothelininhtmmnconges- tive heart failure.Cimulation,1994(89): 1580-1586.
9Mulder P,Richard V,Derurrea C,et al.Role of endogenous endothelin in chronic heart failure.Effect of long-term treatment with an endothelin antagonist on sutural,hemodynamics,and cardiac rmodelling.Circulation, 1997(96): 1976-1982.
